Top-line financials for Japanese drug majors

1 August 2013

Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the country’s largest pharma firm TAKEDA PHARMACEUTICALS (TYO: 4502) reported 3.0% growth in revenues to 410.30 billion yen ($4.18 billion). Operating profit decreased 23.8% to 47.71 billion yen; current profit decreased 20.7% to 52.49 billion yen; net income decreased 66.8% to 29.08 billion yen and earnings per share fell 66.8% to 36.83 yen.

MITSUBISHI TANABE PHARMA (TYO: 4508) reported first-quarter 2014 results with 0.4% decrease in revenues to 103.92 billion yen. Operating profit decreased 13.8% to 16.24 billion yen; current profit decreased 13.1% to 17.06 billion yen; net income fell 3.9% to 10.41 billion yen and EPS decreased 3.9% to 78.43 yen.

DAINIPPON SUMITOMO PHARMA (TYO: 4506) reported a 0.6% increase in revenues to 89.62 billion yen. Operating profit decreased 17.10% to 9.03 billion yen; current profit decreased 17.40% to 9.49 billion yen; net income declined 15.60% to 4.81 billion yen and EPS decreased 16.00% to 12.10 yen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK